Viridian Therapeutics shares are trading higher after the company announced a $225 million public offering of 10,666,600 common shares at $18.75 per share. Additionally, Goldman Sachs raised its price target on the stock from $25 to $31.
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics shares rose following a $225 million public offering and a price target increase by Goldman Sachs from $25 to $31.
September 12, 2024 | 5:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viridian Therapeutics shares increased due to a $225 million public offering and a price target raise by Goldman Sachs from $25 to $31.
The public offering indicates strong investor interest and capital influx, while the price target increase by a major financial institution like Goldman Sachs suggests positive future prospects, both contributing to a likely short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100